Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by losingmyshirton Aug 22, 2021 11:07am
290 Views
Post# 33746051

Why has Kalytera never accomplished anything?

Why has Kalytera never accomplished anything?
 AS FAR AS BOB'S CONCERNED, HE IS ALWAYS ON YTHE RIGHT TRACK. IT ALL SOUNDS ROSY UNTIL THEY PULL THE PLUG AND MOVE ON.

“We are very encouraged by the results we are seeing,” stated Robert Farrell, President and CEO of Kalytera. “We did not anticipate that the results for the low dose cohort would be as positive as they were, and now the interim results for the medium dose cohort are even better. These results will leave little or no room for improvement with the high dose of 300 mg of CBD administered twice daily.”
The results of Study KAL-05 to date are in line with data from the two previous Phase 2a clinical studies that were completed by Dr. Moshe Yeshurun, Kalytera’s Chief Medical Officer, at the Institute of Hematology, Davidoff Center, Rabin Medical Center, Petah Tikva, Israel.
The results from the first of these previous clinical studies were published in Biology of Blood and Marrow Transplantation (Cannabidiol for the Prevention of Graft-versus-Host-Disease after Allogeneic Hematopoietic Cell Transplantation: Results of a Phase II Study, M. Yeshurun et al. / Biology Blood Marrow Transplant 21 (2015) 1770 – 1775). The 48 patients in this study received daily doses of 150 mg of CBD administered twice daily for 7 days prior to their bone marrow transplant procedure and for 30 days after, and, as previously

<< Previous
Bullboard Posts
Next >>